For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 9,707 | 11,111* | 9,605 | 10,394 |
| General and administrative | - | 6,872* | 5,867 | 6,703 |
| Selling, general and administrative | 6,417 | - | - | - |
| Total operating expenses | 16,124 | 17,983* | 15,472 | 17,097 |
| Interest income | 1,442 | 1,894* | 1,903 | 2,080 |
| Other expense | 15 | 1* | 5 | 16 |
| Total other income | 1,427 | 1,893* | 1,898 | 2,064 |
| Net loss | -14,697 | -16,090 | -13,574 | -15,033 |
| Basic EPS | -0.12 | -0.127 | -0.11 | -0.12 |
| Diluted EPS | -0.12 | -0.127 | -0.11 | -0.12 |
| Basic Average Shares | 126,634,782 | 126,259,995 | 126,305,122 | 126,204,632 |
| Diluted Average Shares | 126,634,782 | 126,259,995 | 126,305,122 | 126,204,632 |
Nautilus Biotechnology, Inc. (NAUT)
Nautilus Biotechnology, Inc. (NAUT)